HC Wainwright Weighs in on Reviva Pharmaceuticals Holdings, Inc.’s Q1 2025 Earnings (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.21) EPS.

Separately, Benchmark restated a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Stock Up 2.3 %

RVPH stock opened at $3.09 on Tuesday. The company has a 50-day simple moving average of $3.63 and a 200 day simple moving average of $4.12. The company has a market capitalization of $86.27 million, a P/E ratio of -1.88 and a beta of -0.02. Reviva Pharmaceuticals has a fifty-two week low of $2.67 and a fifty-two week high of $9.25.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. EMC Capital Management boosted its position in shares of Reviva Pharmaceuticals by 1,294.3% during the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company’s stock valued at $613,000 after purchasing an additional 115,028 shares in the last quarter. Armistice Capital LLC lifted its stake in Reviva Pharmaceuticals by 194.0% during the fourth quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock valued at $9,085,000 after purchasing an additional 1,164,000 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in Reviva Pharmaceuticals during the fourth quarter worth approximately $72,000. 63.18% of the stock is owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.